Island Pharmaceuticals: Appoints Sofgen for one-off supply of ISLA-101

Island Pharmaceuticals Appoints Sofgen for one-off supply of ISLA-101

  • Island Pharmaceuticals (ILA) executes a one-off proposal with Sofgen for the manufacture of ISLA-101 for the upcoming Phase 2a PEACH clinical trial in dengue infected subjects
  • The new proposal contains a schedule that has ISLA-101 clinical material being manufactured in mid-August, a six-week delay from most recent estimates
  • The company was looking for alternative manufacturers after its prior manufacturer was unable to provide certainty required to plan effectively
  • The new timeline has been consolidated and the company expects the investigational new drug (IND) application to be filed in October with the trial commencing in November
  • Shares in Island Pharmaceuticals are down 18.8 per cent, trading at 13 cents as of 12:01 pm AEST
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

Business Banking Fintech Slash Reaches Unicorn Status

The fintech startup achieves a valuation of over $1 billion.Highlights: Slash has been valued at over $1 billion.The...

Amex Strengthens Digital Services with AI Expense Management Acquisition

American Express to acquire Hyper to enhance its business offerings.Highlights: American Express announces the acquisition of AI startup...

UK Banks Strengthen Cybersecurity with Anthropics Mythos Model

New collaboration enhances banks' defense against cyber threats.Highlights: UK banks to access Anthropics Mythos model in the upcoming...

UK Banks to Gain Access to Anthropic Cybersecurity Model Next Week

New collaboration enhances cybersecurity for UK banking institutions.Highlights: UK banks set to access Anthropic's cybersecurity model soon.Collaboration aims...